On 26 February 2016, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2015.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 12:30 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will be held in English.
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 566 426 90
UK: +44 203 008 98 01
US: +1 855 831 59 44
Live audience URL:
http://event.onlineseminarsolutions.com/r.htm?e=1121995&s=1&k=A92EC8124510E43D1504F07B4EAEA7FC
(The recording will be made available via the audience URL within three hours after the live broadcast using the same link.)
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
| Media relations | Investor relations |
| Oskar Bosson, Head of Communications | Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 | T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| [email protected] | [email protected] |
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.